menu search

IMRX / Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Read More
Posted: Mar 27 2023, 11:26
Author Name: Zacks Investment Research
Views: 122413

IMRX News  

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

By GlobeNewsWire
October 4, 2023

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for more_horizontal

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

By Seeking Alpha
July 7, 2023

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going more_horizontal

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

By Zacks Investment Research
July 5, 2023

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effective more_horizontal

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 4, 2023

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares more_horizontal

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

By Zacks Investment Research
April 11, 2023

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev more_horizontal

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

By Zacks Investment Research
March 27, 2023

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effective more_horizontal

Why Shares of Immuneering Jumped This Week

By The Motley Fool
March 24, 2023

Why Shares of Immuneering Jumped This Week

Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial. more_horizontal

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

By Zacks Investment Research
March 23, 2023

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig more_horizontal


Search within

Pages Search Results: